September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Recurrences in neovascular age related macular degeneration: are they predictable in a clinical setting?
Author Affiliations & Notes
  • Stefano Erba
    Biomedical and clinical sciences "Luigi Sacco", Sacco Hospital Eye Clinic, University of Milan, Milano, Italy
  • Giulia Delledonne
    Biomedical and clinical sciences "Luigi Sacco", Sacco Hospital Eye Clinic, University of Milan, Milano, Italy
  • Carlo Domenico Bianchi
    Biomedical and clinical sciences "Luigi Sacco", Sacco Hospital Eye Clinic, University of Milan, Milano, Italy
  • Mariano Cozzi
    Biomedical and clinical sciences "Luigi Sacco", Sacco Hospital Eye Clinic, University of Milan, Milano, Italy
  • Alessandro Babbi
    Biomedical and clinical sciences "Luigi Sacco", Sacco Hospital Eye Clinic, University of Milan, Milano, Italy
  • Mario V Cigada
    Biomedical and clinical sciences "Luigi Sacco", Sacco Hospital Eye Clinic, University of Milan, Milano, Italy
  • Ferdinando Bottoni
    Biomedical and clinical sciences "Luigi Sacco", Sacco Hospital Eye Clinic, University of Milan, Milano, Italy
  • Giovanni Staurenghi
    Biomedical and clinical sciences "Luigi Sacco", Sacco Hospital Eye Clinic, University of Milan, Milano, Italy
  • Footnotes
    Commercial Relationships   Stefano Erba, None; Giulia Delledonne, None; Carlo Bianchi, None; Mariano Cozzi, Alcon (F), Bayer AG (F), Heidelberg Engineering (F); Alessandro Babbi, None; Mario Cigada, None; Ferdinando Bottoni, Alcon (F), Bayer AG (F), Novartis (F); Giovanni Staurenghi, Alcon (F), Alcon (C), Allergan (F), Allergan (C), Bayer AG (C), Bayer AG (F), Boheringer (C), Carl Zeiss Meditec (C), Genentech (C), GSK (C), Heidelberg Engineering (C), Heidelberg Engineering (F), Novartis (C), Ocular Instruments (P), OD-OS (C), Optos (C), QLT (C), Quantel Medical (C), Quantel Medical (F), Roche (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3356. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Stefano Erba, Giulia Delledonne, Carlo Domenico Bianchi, Mariano Cozzi, Alessandro Babbi, Mario V Cigada, Ferdinando Bottoni, Giovanni Staurenghi; Recurrences in neovascular age related macular degeneration: are they predictable in a clinical setting?. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3356.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the first recurrence in naive neovascular AMD after three loading doses of Ranibizumab and to assess the risk of subsequent recurrence through retrospective review.

Methods : Design of the study: retrospective review. 93 eyes (87 patients) with naïve CNV (occult-type 1 n=46, classic-type 2 n=23, Retinal Angiomatous Proliferation (RAP)-type 3 n=19 and polypoidal choroidal vasculopathy (PCV) n=5) with no sign of activity (e.g. any intra-, sub-retinal fluid on SD-OCT, new hemorrhage, reduction in visual acuity attributable to neovascular AMD or leakage on fluorescein angiography) after the three loading doses of ranibizumab were enrolled. Only patients with a follow up of 30-45 days between every visit for at least 1 year were included. Recurrences were retreated in pro re nata (PRN) regimen. Exclusion criteria included any previous ophthalmic surgery, except for cataract removal. Eyes with any previous treatment for neovascular AMD (e.g. focal laser, photodynamic therapy, other type of anti-VEGF drugs) were excluded. Survival for the first recurrence was estimated by Kaplan-Meier analysis. Coefficient of variation of the mean recurrence interval was calculated for every patient.

Results : The mean age of patients was 79 years (range 62-91). Mean follow up time was 978 days (range 476-1725). Kaplan Meier analysis showed that the 50% (CI 40%-60%) of neovascular lesions showed signs of reactivation by the forth month (120 days) after the third injection. Subgroup analysis showed that 50% type 3 lesions reactivated by the day 107, type 1 by the day 126, type 2 by the day 175 and PCV by the day 217. Coefficient of variation of the mean recurrence interval was 0,52, interquartile range (IQR) 0,33-0,63.

Conclusions : Although this is a small cohort of patiens with neovascular AMD, our data suggest a clear trend in the first recurrence. RAP-type 3 showed recurrence earlier than occult-type 1 or classic-type 2 lesions. PCV lesions, although a small sample in this cohort, showed a larger interval for the first recurrence. These data may be used to plan a tailored follow up visit after the three loading doses of ranibizumab. Coefficient of variation of the mean recurrence interval showed large intra-individual fluctuations. Recurrences of the neovascular lesions cannot be predicted only on the basis of the first year of follow up.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×